All that doctors need so as to treat cancer successfully is data. And the data should be about several things. According to the co-founder and CEO of Tempus, that is what is missing from today’s medical research system.
There is no shortage of patient data out there, but the medical research system is facing an acute shortage of sources that combine therapeutic data with genomic information. Mr Leftkofsky revealed this recently at the Fortune Brainstorm Healthcare in San Diego.
Lefkosfsky noted that it is easy to gather molecule data. But that is not enough as they need to have the capacity to gather adequate clinical data as well. He continued to explain that this means that other than information concerning the patient’s DNA and DRN makeup, healthcare professionals need to know the type of treatments they are on and how they are responding to the treatment.
A researcher observing breast-cancer patients taking Herceptin should, for example, consider why the drug is working on 40 percent and not 60 percent of the patients. Also, he should seek to find out if there is anything else that is taking place in the life of the patients who are not being helped. Are they on other drugs? Are they diabetic? Leftkofsky noted that this type of information should flow freely between medical researchers and all other medical professionals. Click here to know more.
About Eric Lefkofsky
When Eric Leftkofsky’s wife was diagnosed with breast cancer, he was inspired to start Tempus. As they sat in clinics, he observed that truck drivers had ways to gather better data about how to achieve their objectives at the workplace than oncologists do. He also noted that they often lacked the right data on how some treatments work in some cohort of patients. For this reason, he decided to invent a platform that people starting in oncology and those working on neurological disorders can use to collect data for analysis.
Lefkofsky is also the co-founder of Groupon (NASDAQ: GRPN), an international e-commerce marketplace, and Lightbank, a venture fund that invests mainly in disruptive technology businesses. In 2006, Lefkofsky also established the Lefkofsky Family Foundation to advance high-impact initiatives that make life better in the communities served.